Taysha Gene Therapies (NASDAQ:TSHA) & Gilead Sciences (NASDAQ:GILD) Head to Head Analysis

Taysha Gene Therapies (NASDAQ:TSHA) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Valuation and Earnings

This table compares Taysha Gene Therapies and Gilead Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$15.45 million	29.32	-$111.57 million	($0.20)	-11.05
Gilead Sciences	$28.30 billion	4.08	$5.67 billion	$0.09	1,029.22

Gilead Sciences has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by insiders. Comparatively, 0.2% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Taysha Gene Therapies and Gilead Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	-888.18%	-168.91%	-44.12%
Gilead Sciences	0.45%	29.00%	9.83%

Volatility and Risk

Taysha Gene Therapies has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Taysha Gene Therapies and Gilead Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	0	0	8	0	3.00
Gilead Sciences	0	11	10	2	2.61

Taysha Gene Therapies presently has a consensus price target of $6.38, suggesting a potential upside of 188.46%. Gilead Sciences has a consensus price target of $91.50, suggesting a potential downside of 1.22%. Given Taysha Gene Therapies’ stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Gilead Sciences.

Summary

Gilead Sciences beats Taysha Gene Therapies on 10 of the 15 factors compared between the two stocks.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.